Voyager Therapeutics Inc (VYGR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Voyager Therapeutics Inc stock (VYGR) is currently trading at $4.03. Voyager Therapeutics Inc PS ratio (Price-to-Sales) is 5.79. Analyst consensus price target for VYGR is $14.89. WallStSmart rates VYGR as Sell.
- VYGR PE ratio analysis and historical PE chart
- VYGR PS ratio (Price-to-Sales) history and trend
- VYGR intrinsic value — DCF, Graham Number, EPV models
- VYGR stock price prediction 2025 2026 2027 2028 2029 2030
- VYGR fair value vs current price
- VYGR insider transactions and insider buying
- Is VYGR undervalued or overvalued?
- Voyager Therapeutics Inc financial analysis — revenue, earnings, cash flow
- VYGR Piotroski F-Score and Altman Z-Score
- VYGR analyst price target and Smart Rating
Voyager Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Voyager Therapeutics Inc (VYGR) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Voyager Therapeutics Inc (VYGR) Key Strengths (3)
Revenue surging 144.30% year-over-year
Trading at 1.19x book value, attractively priced
59.87% held by institutions, strong professional interest
Supporting Valuation Data
Voyager Therapeutics Inc (VYGR) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium valuation at 5.8x annual revenue
Supporting Valuation Data
Voyager Therapeutics Inc (VYGR) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 8.7/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.19) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 144.30%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (5.79) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -48.30%, Operating Margin at -172.40%, Profit Margin at -296.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -48.30% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 144.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VYGR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VYGR's Price-to-Sales ratio of 5.79x trades at a deep discount to its historical average of 33.43x (35th percentile). The current valuation is 97% below its historical high of 198.64x set in Jun 2019, and 503% above its historical low of 0.96x in Sep 2021. Over the past 12 months, the PS ratio has expanded from ~2.5x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Voyager Therapeutics Inc (VYGR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Voyager Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 40M with 144% growth year-over-year. The company is currently unprofitable, posting a -296.5% profit margin.
Key Findings
Revenue growing at 144% YoY, reaching 40M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 89% of revenue (36M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -296.5% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -31M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Voyager Therapeutics Inc maintain 144%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Voyager Therapeutics Inc.
Bottom Line
Voyager Therapeutics Inc is a high-conviction growth story with revenue accelerating at 144% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -296.5% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Voyager Therapeutics Inc(VYGR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, is focused on developing treatments for patients with severe neurological diseases. The company is headquartered in Cambridge, Massachusetts.